Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279118 | 1.00 | CHRM3 (0.36) | CHRM3FFAR4OPRM1OPRK1KCNH2 | |
| SCHEMBL28059288 | 0.82 | OPRK1 (0.38) | CHRM3OPRK1KCNH2 | |
| SCHEMBL4278824 | 0.82 | ALDH1A1 (0.33) | CHRM3KMT2A | |
| SCHEMBL4278833 | 0.82 | ALDH1A1 (0.33) | CHRM3KMT2A | |
| SCHEMBL28826953 | 0.76 | POLB (0.40) | CHRM3OPRK1KCNH2 | |
| SCHEMBL4102370 | 0.74 | RBP4 (0.38) | KMT2A | |
| SCHEMBL28719773 | 0.71 | GPR119 (0.34) | OPRM1OPRK1KCNH2 | |
| SCHEMBL28719770 | 0.71 | GPR119 (0.34) | OPRM1OPRK1KCNH2 | |
| SCHEMBL20658831 | 0.71 | TSHR (0.38) | CHRM3OPRM1OPRK1KCNH2 | |
| SCHEMBL21747197 | 0.71 | DPP4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1615878-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| EP-1615878-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | CHRM3 166/4885FFAR4 4620/4885OPRM1 2271/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CHRM3 204/4885FFAR4 4595/4885OPRM1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.